MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Novavax Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

6.01 -7.11

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

6

Max

6.4

Pagrindiniai rodikliai

By Trading Economics

Pajamos

40M

-81M

Pardavimai

3.8M

88M

Pelnas, tenkantis vienai akcijai

-0.52

Pelno marža

-91.755

Darbuotojai

952

EBITDA

52M

-53M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+145.83% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-09

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-140M

1.1B

Ankstesnė atidarymo kaina

13.12

Ankstesnė uždarymo kaina

6.01

Naujienos nuotaikos

By Acuity

79%

21%

355 / 386 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Novavax Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-03-31 14:19; UTC

Pagrindinės rinkos jėgos

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

2025-02-04 18:52; UTC

Pagrindinės rinkos jėgos

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

2024-11-11 14:05; UTC

Pagrindinės rinkos jėgos

Novavax to Move Forward With Covid-19, Influenza Vaccine After FDA Lifts Clinical Hold

2024-10-16 12:59; UTC

Pagrindinės rinkos jėgos

Novavax Says FDA Puts Clinical Hold on Covid-19, Flu Vaccines; Shares Drop

2024-05-13 18:14; UTC

Pagrindinės rinkos jėgos

Novavax Shares Pop Another 50% Following Sanofi Deal

2024-05-10 10:59; UTC

Pagrindinės rinkos jėgos

Novavax Shares Surge on $1.4 Billion Vaccine Licensing Deal with Sanofi

2024-12-30 23:02; UTC

Įsigijimai, susijungimai, perėmimai

Novavax Completes Previously Announced $200M Sale of Czech Republic Manufacturing Site to Novo Nordisk

2024-12-04 07:09; UTC

Įsigijimai, susijungimai, perėmimai

Novavax: Agreement to Close by Dec 30 >NVAX

2024-12-04 07:08; UTC

Įsigijimai, susijungimai, perėmimai

Novavax: Sale Aligns With Plan to Become More Lean Organization, Drive Value From Pipeline Assets & Tech Platform >NVAX

2024-12-04 07:07; UTC

Įsigijimai, susijungimai, perėmimai

Novavax: Deal to Also Reduce Annual Operating Costs by About $80M >NVAX

2024-12-04 07:06; UTC

Įsigijimai, susijungimai, perėmimai

Novavax to Get $190M Cash Payment in 2024, Additional $10M in 2025 >NVAX

2024-12-04 07:06; UTC

Įsigijimai, susijungimai, perėmimai

Novavax: Agreement Provides Company With Significant, Non-Dilutive Capital >NVAX

2024-12-04 07:04; UTC

Įsigijimai, susijungimai, perėmimai

Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200M

2024-11-15 13:34; UTC

Svarbiausios naujienos

Heard on the Street: RFK Jr. Is Spooking Obesity Investors Too -- WSJ

2024-11-15 11:14; UTC

Rinkos pokalbiai

U.S. Vaccine Stocks Fall After Trump Picks Vaccine Skeptic RFK Jr as Health Department Head-- Market Talk

2024-10-16 15:22; UTC

Uždarbis

These Stocks Are Moving the Most Today: ASML, Nvidia, Morgan Stanley, United Airlines, DJT, Novavax, J.B. Hunt, Cisco, and More -- Barrons.com

2024-05-10 20:11; UTC

Uždarbis

These Stocks Moved the Most Today: Novavax, Akamai, Sweetgreen, Taiwan Semi, Moderna, Gen Digital, JFrog, SoundHound, and More -- Barrons.com

2024-05-10 14:49; UTC

Uždarbis
Karštos akcijos

Stocks to Watch Friday: TSMC, Novavax, Nvidia -- WSJ

2024-05-10 10:47; UTC

Įsigijimai, susijungimai, perėmimai

Novavax Gets $1.4 Billion Deal With Sanofi. The Stock Jumps. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Novavax Inc Prognozė

Kainos tikslas

By TipRanks

145.83% į viršų

12 mėnesių prognozė

Vidutinis 14.75 USD  145.83%

Aukščiausias 19 USD

Žemiausias 9 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Novavax Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

4 ratings

2

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

N/A / 7.011Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Weak Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

355 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Novavax Inc

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.